Business UpdateJul 1, 2026, 03:36 PM
20/20 Biolabs Presents OneTest Strategy for Medicare Reimbursement Pathway
AI Summary
20/20 Biolabs presented an investor webinar detailing its OneTest multi-cancer early detection strategy. The presentation highlighted the recent passage of the Multi-Cancer Early Detection Screening Coverage Act, which creates a Medicare reimbursement pathway for such tests by 2028. 20/20 Biolabs believes its OneTest, utilizing biomarker tracking, machine learning, and anti-inflammatory diet integration, is well-positioned for FDA authorization and CMS coverage. The company also outlined its M&A strategy and projected significant revenue growth post-Medicare reimbursement, drawing parallels to Cologuard's success.
Key Highlights
- Investor webinar on July 1, 2026, presented OneTest strategy.
- Multi-Cancer Early Detection Screening Coverage Act passed, enabling Medicare reimbursement by 2028.
- OneTest uses 12 cancer protein tumor markers and inflammation markers.
- Modeled early-stage sensitivity for Liver 88%, Lung 73%, Colorectal 77% with quarterly testing.
- AIDX projects significant revenue growth post-Medicare, citing Cologuard's 133x growth.
- Company plans M&A for vertically/horizontally integrated companies with $2M-$8M revenue.
- OneTest aims for FDA De Novo or PMA authorization and CMS clinical appropriateness.
Price Impact
More from AIDX